Table 1.
Baseline characteristics of 61 Swiss patients with type 2 diabetes who switched to IDegLira
| Characteristic | Valuea | ||
|---|---|---|---|
| All patients n = 61 |
Males n = 35 |
Females n = 26 |
|
| Age (years) | 57.3 (range 25–80) | ||
| Duration of diabetes (years) | 12.5 (range 1–31) | 11.5 | 14.2 |
| Weight (kg) | 96.5 | 103.2 | 87.5 |
| BMI (kg/m2) | 34.3 | 33.9 | 34.9 |
| HbA1c (%) | 9.2 | 9.0 | 9.4 |
| HbA1c (mmol/mol) | 77 | 75 | 79 |
| Systolic blood pressure (mmHg) | 146.4 | 148.5 | 142.5 |
| Diastolic blood pressure (mmHg) | 88.4 | 90.8 | 84.3 |
| Previous oral treatment (n, %)b | |||
| Metformin | 23 (37.7) | ||
| Metformin + sitagliptin | 18 (29.5) | ||
| Gliclazide | 12 (19.7) | ||
| Liraglutide | 8 (13.1) | ||
| Metformin + saxagliptin | 5 (8.2) | ||
| Linagliptin | 3 (4.9) | ||
| Otherc | 10 (16.4) | ||
| Previous insulin treatment (n, %) | |||
| Insulin degludec | 30 (49.2) | ||
| NPH | 9 (14.8) | ||
| Insulin glargine | 5 (8.2) | ||
| Insulin aspart/protamine crystallized insulin aspart | 4 (6.6) | ||
| Insulin aspart/insulin degludec mix | 3 (4.9) | ||
| Insulin detemir | 3 (4.9) | ||
| Insulin lispro/insulin lispro protamine/NPH | 2 (3.3) | ||
| None | 5 (8.2) | ||
BMI body mass index, HbA 1c glycated hemoglobin, IDegLira insulin degludec/liraglutide, NPH neutral protamine Hagedorn
aValues are means unless otherwise specified
bNumbers add to >100% owing to some patients being on multiple treatments
c≤2 patients on any given medication